

Cutting-Edge ARV LNP Screening Platform for High-Efficiency Delivery with ARV L002-LNP

Advanced RNA Vaccine
Technologies, Inc.




rxu@arv-tech.com



www.arv-tech.com








Maryland, USA



ARV Technologies, Thinking Beyond the Possible!

Introduction of ARV Proprietary Lipid Nanoparticle (LNP) –Unleashing ARV's Proprietary L002 LNP for Maximum Efficiency at Minimal Doses



High-Efficiency Screening Platform to Identify New Lipid



** SM-102 LNP is an ionizable lipid employed in the Moderna COVID-19 vaccine, serving as a benchmark



Revolutionizing Vaccine Efficacy: ARV-L002 LNP Induces Robust Immune Responses at a Remarkable 100-Fold Lower Dose than Conventional LNP

2 LNP: SM102 vs ARV L002
3 doses: 0.01, 0.1 and 1 ug mRNA




A comparative study was conducted between SM102 LNP and ARV L002 LNP. Following immunization with three doses (0.01, 0.1, and 1 μ g) Spike-encoding mRNA, the results strongly indicate that ARV-L002 LNP is over 100 times more effective than SM102 LNP in eliciting both antibody and T cell responses..

ARV-L002 and L002-formulated-LNP Exhibited No Toxic Side Effects in vivo




Liver Pathology



Advantages of ARV-L002-Based LNP

Open to collaboration or out-licensing opportunities



Supportive Data Available Upon Request

We are actively seeking collaborators and licensing opportunities for our cutting-edge L002 LNP delivery technology, If you are interested in learning more, please reach out to:

Contact Information

Smou@arv-tech.com

Rxu@arv-tech.com

+1(301)686-3288

Company Website

<https://www.arv-tech.com>

Follow us on

<https://www.linkedin.com/company/arv-technologies-inc/>

